Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials by Steve, Bain
1 
 
Impact of microvascular disease on cardiovascular outcomes in type 2 
diabetes: Results from the LEADER and SUSTAIN 6 clinical trials 
Subodh Verma, MD, PhD1; Stephen C. Bain, MD2; Julie Broe Honoré, MD3; 
Johannes F.E. Mann, MD, PhD4; Michael A. Nauck, MD5; Richard E. Pratley, MD6; 
Søren Rasmussen, MSc PhD3; Maria Sejersten Ripa, MD, DMSc3; Bernard Zinman, 
MD7; John B. Buse, MD, PhD8. 
 
1St. Michael’s Hospital and University of Toronto, Toronto, ON, Canada;  
2Swansea University Medical School, Swansea, UK;  
3Novo Nordisk A/S, Søborg, Denmark;  
4KfH Kidney Center, Munich, and Dept. of Nephrology, Friedrich Alexander 
University of Erlangen, Erlangen, Germany;  
5Diabetes Center Bochum-Hattingen, St Josef Hospital (Ruhr-Universität Bochum), 
Bochum, Germany;  
6AdventHealth Translational Research Institute, Orlando, FL, USA;  
7Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, 
Toronto, ON, Canada;  
8University of North Carolina School of Medicine, Chapel Hill, NC, USA. 
Corresponding author: Subodh Verma, MD, PhD, FRCSC. Address: University of 
Toronto, St. Michael’s Hospital, 30 Bond St, 8th Floor, Bond Wing, Toronto, ON, 




Short running title: Microvasc disease & LEADER/SUSTAIN 6 results  
Word count: 1911/1800 max (excluding abstract and references) 
Number of figures/tables: 2 figures/2 max 
Number of references: 14/15 max 
Article type: Brief report 
3 
 
Abstract (164/180 words) 1 
The randomized, double-blind cardiovascular outcomes trials LEADER 2 
(NCT01179048) and SUSTAIN 6 (NCT01720446) demonstrated cardiovascular risk 3 
reduction in patients with type 2 diabetes treated with liraglutide and semaglutide, 4 
respectively, compared with placebo. This post hoc analysis examined the impact of 5 
microvascular disease at baseline on cardiovascular outcomes in these trials, and 6 
the efficacy of liraglutide (1.8 mg) and once-weekly semaglutide (0.5–1.0 mg) in 7 
patients with and without microvascular disease. In total, 9340 patients from 8 
LEADER and 3297 patients from SUSTAIN 6 were included in this analysis; of these, 9 
5761 and 2356 had a history of microvascular disease at baseline and 3835 and 10 
1640 had a history of both microvascular and macrovascular disease, respectively. 11 
Patients with microvascular disease were shown to have increased risk of major 12 
adverse cardiovascular events (MACE) compared with patients without 13 
microvascular disease (hazard ratio [95% confidence interval] in LEADER: 1.15 14 
[1.03;1.29] p=0.0136; SUSTAIN 6: 1.56 [1.14;2.17] p=0.0064). Liraglutide and 15 
semaglutide consistently reduced cardiovascular risk in patients with and without 16 
microvascular disease. 17 
 18 
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The microvascular complications of type 2 diabetes, namely, nephropathy, 2 
neuropathy and retinopathy, have been progressively linked to an increased risk of 3 
macrovascular complications.1–5 Whether microvascular disease is a marker or 4 
mediator of macrovascular risk in diabetes remains unclear, although common 5 
pathophysiological mechanisms have been suggested.5 These include diabetes-6 
induced changes in endothelial structure and function within the micro- and 7 
macrovasculature, increased production of reactive oxygen species, augmented 8 
mitochondrial superoxide release, and changes in protein kinase C metabolism.5 In 9 
addition, microvascular complications have been linked to an increased risk of heart 10 
failure in diabetes,5 and microvascular rarefaction (vasculopenia) has emerged as an 11 
important pathophysiological component of diabetic heart failure.6 12 
 The relationship between microvascular disease and macrovascular risk has 13 
not been thoroughly investigated in contemporary cardiovascular (CV) outcomes 14 
trials. Compared with prior observational and clinical studies, these trials have been 15 
conducted in the context of guideline-recommended background therapy including 16 
statins, blood pressure control, renin-angiotensin system inhibitors and glycemic 17 
control.7 Therefore, whether or not the relationship between microvascular 18 
complications and macrovascular risk persists remains an important question. 19 
Additionally, the relationship of microvascular disease superimposed on established 20 
macrovascular disease is poorly characterized. We investigated these questions in 21 
LEADER and SUSTAIN 6, which studied liraglutide and semaglutide in people with 22 
type 2 diabetes and CV risk.8,9 Specifically, we evaluated the relationship between 23 
microvascular disease and major CV events and the efficacy of glucagon-like 24 




LEADER was a randomized, double-blind, CV outcomes trial of liraglutide (1.8 mg) 2 
versus placebo in 9340 patients with type 2 diabetes and high CV risk.9 Similarly, 3 
SUSTAIN 6 assessed CV outcomes with once-weekly semaglutide (0.5–1.0 mg) 4 
versus placebo in 3297 patients with type 2 diabetes and high CV risk.8 The primary 5 
major adverse CV events (MACE) outcome in both trials was a composite of CV 6 
death, non-fatal myocardial infarction (MI), or non-fatal stroke. The key secondary 7 
CV outcome (expanded MACE) also included coronary revascularization, or 8 
hospitalization for unstable angina or heart failure. Protocols were approved by 9 
ethics committees or institutional review boards at each center. All patients provided 10 
informed consent.  11 
Microvascular disease at baseline was defined as investigator-reported 12 
history of nephropathy (microalbuminuria, macroalbuminuria, or overt proteinuria 13 
with normal serum creatinine/creatinine clearance; or chronic renal failure), 14 
retinopathy, or peripheral neuropathy.8,9 Macrovascular disease at baseline was 15 
defined as MI, percutaneous coronary intervention (PCI) or coronary artery bypass 16 
grafting (CABG), angina pectoris, asymptomatic cardiac ischemia, stroke, transient 17 
ischemic attack, or ≥50% coronary, intracranial, carotid or peripheral artery stenosis.  18 
Time to first CV event (hazard ratio [HR]) by microvascular and/or 19 
macrovascular disease at baseline was calculated using a Cox proportional hazards 20 
model with subgroup (microvascular/macrovascular disease yes/no) as a factor, 21 
adjusted for treatment. Treatment effects (liraglutide and semaglutide versus 22 
placebo) within subgroups were estimated using a Cox proportional hazards model 23 
with treatment, subgroup, and the interaction of both as factors, adjusted for baseline 24 
covariates: age, antihyperglycemic medication, geographic region, history of MI or 25 
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stroke, renal function (estimated glomerular filtration rate [eGFR]), sex, and smoking 1 
status. For SUSTAIN 6, the model was stratified for factors used for randomization.8 2 
Possible interactions between subgroup and randomized treatment were assessed 3 
using the Cox interaction test (quantitative interactions; p<0.05 indicates a different 4 
magnitude of treatment effect across subgroups) and the Gail-Simon test (qualitative 5 
interactions; p<0.05 indicates an increased risk with treatment in one subgroup and a 6 
decreased risk with treatment in another).  7 
Results 8 
Baseline characteristics 9 
A total of 12,637 patients with type 2 diabetes were included in this exploratory 10 
research. In LEADER and SUSTAIN 6, respectively, 5761 (62%) and 2356 (71%) 11 
patients had a history of microvascular disease at baseline (Figure 1). Furthermore, 12 
3835 patients in LEADER (41%) and 1640 patients in SUSTAIN 6 (50%) had a 13 
history of both microvascular and macrovascular disease. At baseline, patients with 14 
≥1 microvascular disease had a higher mean age, longer diabetes duration, more 15 
frequent insulin use, higher systolic blood pressure, and lower eGFR than those 16 
without microvascular disease (Table S1). Fewer patients with microvascular 17 
disease had a history of MI (LEADER: 26% vs 36%; SUSTAIN 6: 28% vs 43%), but 18 
more had peripheral artery disease (LEADER: 14% vs 9%; SUSTAIN 6: 15% vs 19 
10%) and heart failure (LEADER: 14.1% vs 13.7%; SUSTAIN 6: 19.3% vs 12.6%) 20 
than those without microvascular disease. Use of loop diuretics was more common 21 
in patients with microvascular disease than those without (LEADER: 20% vs 14%; 22 
SUSTAIN 6: 19% vs 11%), but other background therapies, including inhibitors of the 23 
renin-angiotensin system and lipid-lowering medications, were balanced between 24 
groups (data not shown). 25 
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Risk of CV events according to microvascular disease regardless of treatment 1 
Patients with ≥1 microvascular disease at baseline had a higher risk of MACE (HR 2 
[95% confidence interval (CI)] in LEADER: 1.15 [1.03;1.29] p=0.013; SUSTAIN 6: 3 
1.56 [1.14;2.17] p=0.006), expanded MACE, although not statistically significant, 4 
(LEADER: 1.08 [0.98;1.18] p=0.11; SUSTAIN 6: 1.16 [0.93;1.44] p=0.19), and CV 5 
death (LEADER: 1.28 [1.06;1.54] p=0.0102; SUSTAIN 6: 2.65 [1.48;5.17] p=0.002) 6 
compared with patients without microvascular disease. Furthermore, in LEADER, the 7 
risk of CV events was higher in patients with one microvascular disease versus 8 
patients without, and appeared to increase further in patients with >1 microvascular 9 
disease (Figure 2). The same pattern was not evident for SUSTAIN 6 (Figure 2). 10 
Placebo event rates for MACE (events per 100 patient-years of observation) in 11 
LEADER and SUSTAIN 6 were: 2.5 and 2.7, respectively, in patients with history of 12 
microvascular disease alone; 3.8 and 4.1, respectively, in patients with isolated 13 
macrovascular disease; and 5.0 and 5.4, respectively, in those with both 14 
microvascular and macrovascular disease.  15 
CV efficacy of liraglutide and semaglutide according to microvascular disease at 16 
baseline 17 
Liraglutide and semaglutide reduced CV outcomes compared with placebo in 18 
patients with a history of microvascular disease; no heterogeneity in treatment 19 
effects was observed for subgroups by microvascular disease, with the exception of 20 
the neuropathy (yes/no) subgroups for MACE in SUSTAIN 6 (Figure S1).  21 
Conclusions 22 
In this analysis from LEADER and SUSTAIN 6, we found that the presence of 23 
microvascular disease was independently associated with an increased risk of 24 
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MACE. Furthermore, MACE risk was markedly higher in patients who had both 1 
microvascular and macrovascular complications at baseline.  2 
Liraglutide and semaglutide consistently reduced major CV outcomes in 3 
patients with microvascular disease. There is currently a lack of data around the 4 
impact of microvascular disease in type 2 diabetes on CV risk, and this study 5 
represents an important addition, providing data from two major contemporary 6 
clinical trials in a large number of patients. 7 
Our findings are consistent with previous studies that demonstrated an 8 
association between microvascular disease burden (e.g. retinopathy, nephropathy, 9 
and peripheral neuropathy) and an increased risk of future CV disease; an 10 
association shown to be independent of major established CV risk factors.1,10–11 The 11 
association between micro- and macrovascular complications has been reviewed by 12 
Laakso,5 highlighting an association between severity of diabetic retinopathy and 13 
occurrence of CV events, including CV death and fatal stroke, after adjusting for 14 
multiple factors. Notably, an increased risk of CV events was identified in patients 15 
with non-proliferative diabetic retinopathy (HR [95% CI], 1.8 [1.2–2.3]) compared with 16 
patients with proliferative diabetic retinopathy (4.1 [2.0–8.9]) over a 5-year follow-up.  17 
The connection between microvascular diseases and CV events is further 18 
supported by emerging experimental and clinical data.1,6 A post hoc analysis of 19 
EMPA-REG OUTCOME investigated the risk of microvascular disease on CV 20 
outcomes using Cox proportional hazards models. The presence of one, two, or 21 
three microvascular diseases at baseline corresponded to increasing HRs for MACE 22 
(HR 1.09, 1.15, and 1.65, respectively; p for trend=0.0552), although presence of 23 
any microvascular disease at baseline was not statistically associated with increased 24 
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risk of 3-point MACE.1 However, a statistically significant association between 1 
microvascular disease at baseline and MACE was identified in the ADVANCE trial 2 
and ADVANCE-ON post-trial study (1.64 [1.37–1.97] p<0.001) after a median follow-3 
up of 9.9 years.11 One could speculate that the lower HRs seen in EMPA-REG 4 
OUTCOME, compared with ADVANCE and ADVANCE-ON, may be due to effective 5 
background diabetes therapies and treatments for CV risk factors that were not 6 
available to patients in the ADVANCE studies prior to the trial commencement.12  7 
While we did not evaluate the relationship between microvascular risk and 8 
heart failure, there are emerging experimental and clinical data to support this link.1,6 9 
Indeed, in EMPA-REG OUTCOME, microvascular disease history was a stronger 10 
determinant of heart failure (1.63 [1.06–2.49] p=0.0245) compared with MACE (1.16 11 
[0.92–1.48] p=0.2144). 12 
In addition to suggesting an association between microvascular complications 13 
and CV events, the results of this exploratory research show that liraglutide and 14 
semaglutide reduce major CV events in patients with microvascular disease. Our 15 
findings are consistent with a previous post hoc analysis of LEADER which showed 16 
that liraglutide reduced risk of CV outcomes and all-cause mortality in participants 17 
with and without chronic kidney disease (subgroups defined by low eGFR and/or 18 
elevated albuminuria).3 19 
Micro- and macrovascular disease may have several pathophysiological 20 
similarities.3 It is suggested that hyperglycemia induces the over-production of 21 
mitochondrial superoxide, activating the polyol, hexosamine and protein kinase C 22 
pathways, and encourages formation of advanced glycation end products. These 23 
hyperglycemia outcomes result in intracellular oxidative stress, changes in 24 
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glomerular cell gene expression and cardiomyocyte function, and vascular 1 
pathology, giving rise to micro- and macrovascular complications.3 Gerstein et al. 2 
further explored the shared pathophysiology of micro- and macrovascular 3 
complications. The authors highlighted evidence that pathogenic microvascular 4 
changes in the retina, including inflammation, macular edema, and capillary 5 
proliferation, are likely to occur in the vasa vasorum supplying major blood vessels, 6 
such as the carotid artery.13 The resulting ischemia, intimal or medial thickening, 7 
increased collagen synthesis, and reverse cholesterol transport in such 8 
macrovasculature may add to the burden on heart and compromise cardiac 9 
performance.13 Additionally, some experimental studies point towards 10 
neovascularization as a common link between microvascular and macrovascular 11 
complications. Neovascularization is an early feature of atherosclerotic plaques and 12 
plays a role in plaque rupture,14 and is also a feature of microvascular diseases, 13 
such as retinopathy.  14 
Our findings have prognostic implications for including the early assessment 15 
of microvascular complications in addition to the more traditional CV risk factors in 16 
type 2 diabetes management. The presence of early microvascular disease, such as 17 
retinopathy, might indicate a need for more careful and thorough cardiac assessment 18 
and follow-up. The study also has value in helping to better define categories of risk 19 
in individual patients with type 2 diabetes.  20 
Our results should be interpreted with a degree of caution as this analysis was 21 
not prespecified in either LEADER or SUSTAIN 6. The same limitations of the 22 
primary analyses of the trials relating to the high-risk patient populations that restrict 23 
generalization of results and limited follow-up periods also apply to this post hoc 24 
analysis. Furthermore, although our analyses were performed in large, and generally 25 
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well-matched patient populations, with adjustment for various baseline covariates, 1 
there is still the possibility of residual confounding from other sources. For example, 2 
the majority of both populations had established CV disease, chronic kidney disease 3 
or both at randomization (81.3% in LEADER; 83.0% in SUSTAIN 6; with others 4 
having CV risk factors only),8,9 which may have confounded analysis of 5 
microvascular complications. Our data support the 2019 ESC guidelines, which 6 
identify patients with nephropathy and retinopathy as being at high risk for CV 7 
events.7 However, nephropathy and retinopathy were not measured as a primary 8 
endpoint and presence at baseline relied on investigator-reported medical 9 
histories.8,9 10 
Concluding, a history of microvascular disease is associated with heightened 11 
macrovascular risk in LEADER and SUSTAIN 6. Liraglutide and semaglutide 12 
consistently reduced risk in people with and without a history of microvascular 13 
disease.   14 
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Figure legends 1 
Figure 1 2 
LEADER and SUSTAIN 6 patient populations by microvascular disease at 3 
baseline: Venn diagram of number (%) of patients according to microvascular 4 
diseases at baseline in LEADER and SUSTAIN 6 5 
 6 
 7 
Figure 2 8 
Cardiovascular events by history of microvascular disease in LEADER and 9 
SUSTAIN 6: Kaplan-Meier estimates (based on number of microvascular diseases 10 
at baseline) of A, time to first MACE (composite of CV death, non-fatal myocardial 11 
infarction, or non-fatal stroke) and B, time to first expanded MACE (composite also 12 
including coronary revascularization, or hospitalization for unstable angina or heart 13 
failure), in LEADER and SUSTAIN 6  14 
CV, cardiovascular; MACE, major adverse cardiovascular events 15 
